Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho Oncology, Basilea, Eisai, Zymeworks, BeiGene, Xencor, BMS, Leap
August 28, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biliary Tract Cancer Market to Register Stunning Growth by 2032, Examines DelveInsight | Key Companies to Watch Out - Merck, AstraZeneca, Taiho...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
June 22, 2023 16:05 ET
|
Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
May 04, 2023 08:30 ET
|
Compass Therapeutics
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half...
Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023 08:30 ET
|
Compass Therapeutics
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
January 19, 2023 17:00 ET
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 01, 2022 08:00 ET
|
Compass Therapeutics
Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A Phase 2 trial of CTX-009 as a monotherapy in...
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2022 08:00 ET
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
May 24, 2022 11:04 ET
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
May 23, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...